Alvotech hf. is a vertically integrated biotechnology company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. The company leverages a purpose built platform that spans research and development, cell line creation, cGMP manufacturing, clinical testing and regulatory approvals. Alvotech hf. aims to improve health outcomes by broadening access to affordable biosimilars across major therapeutic areas such as immunology, ophthalmology, oncology and hematology. Since its founding in 2013 the firm has built a portfolio that includes five approved biosimilars and more than thirty product candidates targeting diseases like rheumatoid arthritis, psoriasis, Crohn’s disease, age related macular degeneration and various cancers. The integrated model allows Alvotech hf. to control the entire value chain from early discovery to final product delivery.

Alvotech hf. generates revenue through two primary channels: product sales made by its commercial partners and licensing income from those partnerships. In 2025 product sales totaled $276.3 million, composed of $152.2 million from Europe, $105.9 million from the United States and $18.2 million from the rest of the world. License and other revenue reached $310.1 million, consisting of upfront payments, milestone payments and royalties earned under agreements with partners such as Teva, STADA and Advanz Pharma. Partners pay upfront fees upon signing, milestone payments linked to development progress, regulatory approvals and commercial launches, and ongoing royalties calculated as a percentage of net sales. This revenue model enables Alvotech hf. to monetize its biosimilar portfolio while outsourcing distribution and marketing to experienced regional partners.

Within the biosimilars industry Alvotech hf. competes with large originator biologics companies and other dedicated biosimilar manufacturers such as Amgen, Biocon, Celltrion, Samsung Bioepis, Sandoz and Fresenius Kabi. Its competitive advantage stems from a fully integrated platform that provides control over quality, capacity allocation and cost efficiencies across the value chain. The company’s strategy of forming regional commercialization partnerships with leaders like Teva, STADA and Advanz Pharma enables rapid market entry while reducing reliance on a single distributor. Continuous investment in R&D and a deep pipeline of over thirty candidates targeting immunology, ophthalmology, oncology and hematology further strengthen its position relative to peers. Specific product lines face competition from approved biosimilars; for example AVT02 rivals products from Amgen, Biocon and Samsung Bioepis, while AVT04 contends with offerings from Intas, Formycon and Accord. Alvotech hf.’s ability to leverage in house cell line development, cGMP facilities and analytical capabilities allows it to maintain consistent product quality and to respond quickly to evolving market needs.

Alvotech hf. serves a network of pharmaceutical partners that include Teva in the United States, STADA in Europe, Advanz Pharma across the EEA UK Switzerland Canada Australia and New Zealand, Fuji Pharma in Japan, JAMP Pharma in Canada and Dr. Reddy's Laboratories for global markets. These partners in turn distribute the biosimilars to hospitals, clinics, pharmacies and ultimately to patients suffering from conditions such as rheumatoid arthritis, psoriasis, ophthalmic diseases and cancer. By relying on partners with established sales forces the company achieves broad geographic reach without maintaining its own direct sales organization. The partnership structure also provides Alvotech hf. with access to local market expertise, reimbursement knowledge and established relationships with payors, which are critical for successful commercialization of complex biologics. Additional collaborators such as Kashiv Biosciences for AVT23 and Dr. Reddy's for AVT32 further expand the company’s reach into specialty therapeutic areas.